131 related articles for article (PubMed ID: 38843203)
1. Reprogrammed IDO-Induced Immunosuppressive Microenvironment Synergizes with Immunogenic Magnetothermodynamics for Improved Cancer Therapy.
Wang X; Yan B; Li H; Yuan J; Guo J; Wang S; Dai P; Liu X
ACS Appl Mater Interfaces; 2024 Jun; 16(24):30671-30684. PubMed ID: 38843203
[TBL] [Abstract][Full Text] [Related]
2. Comparison study of different indoleamine-2,3 dioxygenase inhibitors from the perspective of pharmacodynamic effects.
Jiang X; Li X; Zheng S; Du G; Ma J; Zhang L; Wang H; Tian J
Int J Immunopathol Pharmacol; 2020; 34():2058738420950584. PubMed ID: 32962460
[TBL] [Abstract][Full Text] [Related]
3. Plasmon-Driven Catalytic Chemotherapy Augments Cancer Immunotherapy through Induction of Immunogenic Cell Death and Blockage of IDO Pathway.
Ding Y; Sun Z; Gao Y; Zhang S; Yang C; Qian Z; Jin L; Zhang J; Zeng C; Mao Z; Wang W
Adv Mater; 2021 Aug; 33(34):e2102188. PubMed ID: 34278622
[TBL] [Abstract][Full Text] [Related]
4. Combinatorial antitumor effects of indoleamine 2,3-dioxygenase inhibitor NLG919 and paclitaxel in a murine B16-F10 melanoma model.
Meng X; Du G; Ye L; Sun S; Liu Q; Wang H; Wang W; Wu Z; Tian J
Int J Immunopathol Pharmacol; 2017 Sep; 30(3):215-226. PubMed ID: 28604143
[TBL] [Abstract][Full Text] [Related]
5. Indoleamine 2,3-dioxygenase: As a potential prognostic marker and immunotherapeutic target for hepatocellular carcinoma.
Asghar K; Farooq A; Zulfiqar B; Rashid MU
World J Gastroenterol; 2017 Apr; 23(13):2286-2293. PubMed ID: 28428708
[TBL] [Abstract][Full Text] [Related]
6. Triple drugs co-delivered by a small gemcitabine-based carrier for pancreatic cancer immunochemotherapy.
Sun J; Wan Z; Chen Y; Xu J; Luo Z; Parise RA; Diao D; Ren P; Beumer JH; Lu B; Li S
Acta Biomater; 2020 Apr; 106():289-300. PubMed ID: 32004652
[TBL] [Abstract][Full Text] [Related]
7. Redox-Activated Porphyrin-Based Liposome Remote-Loaded with Indoleamine 2,3-Dioxygenase (IDO) Inhibitor for Synergistic Photoimmunotherapy through Induction of Immunogenic Cell Death and Blockage of IDO Pathway.
Liu D; Chen B; Mo Y; Wang Z; Qi T; Zhang Q; Wang Y
Nano Lett; 2019 Oct; 19(10):6964-6976. PubMed ID: 31518149
[TBL] [Abstract][Full Text] [Related]
8. Reversal of HMGA1-Mediated Immunosuppression Synergizes with Immunogenic Magnetothermodynamic for Improved Hepatocellular Carcinoma Therapy.
Yan B; Liu C; Li H; Wen N; Jiao W; Wang S; Zhang Y; Zhang T; Zhang H; Lv Y; Fan H; Liu X
ACS Nano; 2023 May; 17(10):9209-9223. PubMed ID: 37162457
[TBL] [Abstract][Full Text] [Related]
9. Enhanced cancer therapy through synergetic photodynamic/immune checkpoint blockade mediated by a liposomal conjugate comprised of porphyrin and IDO inhibitor.
Huang Z; Wei G; Zeng Z; Huang Y; Huang L; Shen Y; Sun X; Xu C; Zhao C
Theranostics; 2019; 9(19):5542-5557. PubMed ID: 31534502
[TBL] [Abstract][Full Text] [Related]
10. Breast Cancer Chemo-immunotherapy through Liposomal Delivery of an Immunogenic Cell Death Stimulus Plus Interference in the IDO-1 Pathway.
Lu J; Liu X; Liao YP; Wang X; Ahmed A; Jiang W; Ji Y; Meng H; Nel AE
ACS Nano; 2018 Nov; 12(11):11041-11061. PubMed ID: 30481959
[TBL] [Abstract][Full Text] [Related]
11. Nanoconjugates to enhance PDT-mediated cancer immunotherapy by targeting the indoleamine-2,3-dioxygenase pathway.
Yang X; Zhang W; Jiang W; Kumar A; Zhou S; Cao Z; Zhan S; Yang W; Liu R; Teng Y; Xie J
J Nanobiotechnology; 2021 Jun; 19(1):182. PubMed ID: 34127005
[TBL] [Abstract][Full Text] [Related]
12. Effect of surface modification on the distribution of magnetic nanorings in hepatocellular carcinoma and immune cells.
Jiao W; Wen N; Wang S; Zhou G; Lu Q; Su Z; Wang X; Hu S; Xie Y; Zhang N; Liu X
J Mater Chem B; 2024 Mar; 12(10):2628-2638. PubMed ID: 38376513
[TBL] [Abstract][Full Text] [Related]
13. Graphene Oxide-Grafted Magnetic Nanorings Mediated Magnetothermodynamic Therapy Favoring Reactive Oxygen Species-Related Immune Response for Enhanced Antitumor Efficacy.
Liu X; Yan B; Li Y; Ma X; Jiao W; Shi K; Zhang T; Chen S; He Y; Liang XJ; Fan H
ACS Nano; 2020 Feb; 14(2):1936-1950. PubMed ID: 31961656
[TBL] [Abstract][Full Text] [Related]
14. Ultra-small Janus nanoparticle-induced activation of ferroptosis for synergistic tumor immunotherapy.
Wang J; Wang Z; Li L; Wang M; Chang J; Gao M; Wang D; Li C
Acta Biomater; 2024 Jun; 181():362-374. PubMed ID: 38663684
[TBL] [Abstract][Full Text] [Related]
15. Self-delivery oxidative stress amplifier for chemotherapy sensitized immunotherapy.
Zhao L; Zheng R; Liu L; Chen X; Guan R; Yang N; Chen A; Yu X; Cheng H; Li S
Biomaterials; 2021 Aug; 275():120970. PubMed ID: 34146889
[TBL] [Abstract][Full Text] [Related]
16. Dual-Responsive Supramolecular Polymeric Nanomedicine for Self-Cascade Amplified Cancer Immunotherapy.
Hu W; Ye B; Yu G; Yang H; Wu H; Ding Y; Huang F; Wang W; Mao Z
Adv Sci (Weinh); 2024 May; 11(20):e2305382. PubMed ID: 38493499
[TBL] [Abstract][Full Text] [Related]
17. Indoleamine 2,3-dioxygenase provides adaptive resistance to immune checkpoint inhibitors in hepatocellular carcinoma.
Brown ZJ; Yu SJ; Heinrich B; Ma C; Fu Q; Sandhu M; Agdashian D; Zhang Q; Korangy F; Greten TF
Cancer Immunol Immunother; 2018 Aug; 67(8):1305-1315. PubMed ID: 29959458
[TBL] [Abstract][Full Text] [Related]
18. NLG919/cyclodextrin complexation and anti-cancer therapeutic benefit as a potential immunotherapy in combination with paclitaxel.
Xu J; Ren X; Guo T; Sun X; Chen X; Patterson LH; Li H; Zhang J
Eur J Pharm Sci; 2019 Oct; 138():105034. PubMed ID: 31382032
[TBL] [Abstract][Full Text] [Related]
19. Oxaliplatin-/NLG919 prodrugs-constructed liposomes for effective chemo-immunotherapy of colorectal cancer.
Shen F; Feng L; Zhu Y; Tao D; Xu J; Peng R; Liu Z
Biomaterials; 2020 Oct; 255():120190. PubMed ID: 32563943
[TBL] [Abstract][Full Text] [Related]
20. IDO-inhibitor potentiated immunogenic chemotherapy abolishes primary tumor growth and eradicates metastatic lesions by targeting distinct compartments within tumor microenvironment.
Li Q; Liu J; Fan H; Shi L; Deng Y; Zhao L; Xiang M; Xu Y; Jiang X; Wang G; Wang L; Wang Z
Biomaterials; 2021 Feb; 269():120388. PubMed ID: 33172606
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
